NCT01245816撤回3 期
A Randomized Phase III Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 主要终点
- Efficacy of Eflornithine plus Sulindac compared to Eflornithine alone and Sulindac alone determined by change in the number of polyps 2 mm or greater in a defined focal area of the rectum or pouch at baseline and after completion of the study treatment.
研究概览
简要总结
The purpose of this phase III study is to evaluate the safety and efficacy of the combination of eflornithine and sulindac compared to single agent sulindac or eflornithine in reducing the number of polyps in patients with familial adenomatous polyposis (FAP).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of phenotypic Familial Adenomatous Polyposis (FAP) of the colorectum based on meeting the criteria in one of two groups: Group 1-Greater than 100 adenomatous colorectal polyps prior to age
- •Group 2-Greater than 10 adenomatous polyps and age <40 or greater than 25 polyps and age >40; combined with a dominant family history or genotype: More than 100 polyps in a first-degree relative; More than 25 polyps in 2 relatives in 2 generations, including a first-degree family member; Genetic diagnosis in a relative; Genetic diagnosis by in vitro synthesized truncated protein or similar assay.
- •No colorectal surgery or prior colon surgery for polyposis at least 1 year prior (total abdominal colectomy with ileal-rectal anastomosis, or total proctocolectomy with ilea pouch-anal reconstruction.
- •Baseline endoscopy
- •If no prior colorectal surgery, at least 3 polyps in a cluster each ≥ 2 mm in diameter; or
- •If rectum is in situ and to be assessed, baseline rectal segment endoscopy documenting 3 or more rectal polyps each at least 2 mm in diameter in a defined cluster and/or at least 6 polyps, ≥ 2 mm in diameter, in the distal 10 cm of rectum
- •If ileal pouch neo-rectum is in place, 3 or more pouch polyps in a cluster ≥ 2 mm in diameter, or at least 6 polyps, ≥ 2 mm in diameter, in the distal 10 cm of pouch.
- •Clinical/pathological grading of duodenal polyps will utilize the Spigelman Classification.
- •Hematopoietic: no significant hematologic dysfunction; WBC ≥3,000/mm3; platelet count ≥100,000/mm3; hemoglobin ≥10g/dL; no known or prior clinical coagulopathy.
- •Hepatic: bilirubin ≤ 1.5 times ULN; AST and ALT ≤ 1.5 times ULN; Alkaline phosphatase ≤ 1.5 times ULN.
- •Renal: No significant renal dysfunction; creatinine ≤ 1.5 times ULN.
- •Hearing: no clinically significant hearing loss that affects everyday life.
- •Not pregnant or nursing.
- •Negative serum pregnancy test if female of child-bearing potential.
- •Absence of gross blood in stool.
- •Fertile patients must use effective contraception.
- •Stool occult blood either negative or minimal (1+).
- •No prior hypersensitivity to cyclooxygenase-2 inhibitors, sulfonamides, NSAIDs, or salicylates; no NSAID associated symptoms of gastritis.
- •No discrete gastric or duodenal ulcer greater than 5 mm within the past year except Helicobacter pylori-related peptic ulcer disease treated successfully with antibiotics (as documented by an endoscopy.
- •No invasive malignancy within the past 5 years except stage I or II colon or rectal cancer or resected nonmelanomatous skin cancer.
- •No other significant medical or psychiatric problems that would preclude study participation.
- •No chronic adrenocorticosteroids.
- •No prior pelvic irradiation.
- •At least 3 months since prior investigational agents.
- •Patients may not be receiving or plan to receive corticosteroids.
- •Concomitant NSAID use outside this study may not exceed 4 days per month.
- •Use of 81 mg daily aspirin or 650 mg aspirin not more than once a week.
- •No concurrent warfarin, fluconazole, or lithium.
- •Must be willing and able to sign informed consent.
排除标准
- •High Risk for cardiovascular disease including clinical diabetes mellitus (Type I or II) requiring glycemic medications; Prior personal history of cardiovascular disease or, two or more of the following - hypertension or use of anti-hypertensive medications, hyperlipidemia or use of lipid-lowering medications or current smoker.
- •Hearing loss that affects everyday life and or for which a hearing aid is required.
研究组 & 干预措施
Eflornithine plus Sulindac
Experimental
Eflornithine 500 mg and Sulindac 150 mg
干预措施: Eflornithine plus Sulindac (Drug)
Elfornithine plus Placebo
Active Comparator
Eflornithine 500 mg and Placebo
干预措施: Eflornithine plus Placebo (Drug)
Sulindac plus Placebo
Active Comparator
Sulindac 150 mg and Placebo
干预措施: Sulindac plus Placebo (Drug)
结局指标
主要结局
Efficacy of Eflornithine plus Sulindac compared to Eflornithine alone and Sulindac alone determined by change in the number of polyps 2 mm or greater in a defined focal area of the rectum or pouch at baseline and after completion of the study treatment.
时间窗: 6 months from the start of treatment.
次要结局
- Change in number of polyps 2 mm or greater in the distal 10 cm of rectum or pouch.(6 months from the start of treatment.)
- Qualitative change in overall colon/rectum/pouch polyp burden (number and size).(6 months from the start of treatment.)
- Presence of high grade dysplasia or villous adenoma in any polyp resected.(6 months from the start of treatment.)
研究者
相似试验
已完成
3 期
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)Familial Adenomatous PolyposisNCT01483144Cancer Prevention Pharmaceuticals, Inc.171
已完成
3 期
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon PolypsPrecancerous ConditionNCT00118365National Cancer Institute (NCI)375
已完成
3 期
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate CancerProstate CancerNCT00988208Celgene1,059
已完成
3 期
Japanese P III vs Voglibose and PlaceboDiabetes Mellitus, Type 2NCT00654381Boehringer Ingelheim561
已完成
3 期
MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT00854035Ono Pharmaceutical Co. Ltd266